In this study, we conducted a retrospective analysis to evaluate AXL and GAS6 expression levels in NSCLC patients with BM by standard immunohistochemistry (IHC) and further interrogated its potential role in survival outcome prognosis. Here, AXL is linked to non-small cell lung carcinoma.